TY - JOUR
T1 - Probiotic treatment restores normal developmental trajectories of fear memory retention in maternally separated infant rats
AU - Peng, Hsuan Hui
AU - Tsai, Tsung Chih
AU - Huang, Wan Yu
AU - Wu, Hung Ming
AU - Hsu, Kuei Sen
N1 - Funding Information:
The authors declare no conflict of interests. This work was supported by research grants from the National Health Research Institute ( NHRI-EX107-10613NI ), Taiwan and the Ministry of Science and Technology ( 106-2320-B-006-026-MY3 and 107-2320-B-006-037-MY3 ), Taiwan.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/7/15
Y1 - 2019/7/15
N2 - Early life stress (ELS) can affect brain development and increase lifetime prevalence of psychiatric illnesses. However, the effective therapeutic interventions to ameliorate the deleterious effects of ELS have not yet been well established. Here, we confirmed that maternal separation (MS) for 3 h daily between postnatal days 2–14, a frequently used experimental model of ELS, resulted in early expression of adult-like fear memory retention in male infant rats. Administration of a probiotic formulation, Lacidofil ® (95% Lactobacillus rhamnosus R0011 and 5% Lactobacillus helveticus R0052), during the separation period, prevented the precocious transition to adult-like fear memory retention in MS infant rats. Consonant with this effect, probiotic treatment also ameliorated the MS-induced increases in anxiety-like behavior as measured by the elevated plus maze and the light-dark box tests. In addition, probiotic treatment reduced MS-induced increases in neuronal activation and brain-derived neurotrophic factor protein levels in the basolateral nucleus of amygdala (BLA) after auditory fear conditioning. Furthermore, we found that probiotic treatment significantly rescued the heightened hypothalamic-pituitary-adrenal (HPA) axis response to restraint stress in MS infant rats. Taken together, these findings suggest that probiotics can restore normal developmental trajectories of fear memory retention in MS infant rats, at least in part by normalizing HPA axis abnormalities, and that the BLA serves as a critical node to mediate these interventions. Thus, we offer a potential therapeutic intervention to protect children against the harmful effects of ELS.
AB - Early life stress (ELS) can affect brain development and increase lifetime prevalence of psychiatric illnesses. However, the effective therapeutic interventions to ameliorate the deleterious effects of ELS have not yet been well established. Here, we confirmed that maternal separation (MS) for 3 h daily between postnatal days 2–14, a frequently used experimental model of ELS, resulted in early expression of adult-like fear memory retention in male infant rats. Administration of a probiotic formulation, Lacidofil ® (95% Lactobacillus rhamnosus R0011 and 5% Lactobacillus helveticus R0052), during the separation period, prevented the precocious transition to adult-like fear memory retention in MS infant rats. Consonant with this effect, probiotic treatment also ameliorated the MS-induced increases in anxiety-like behavior as measured by the elevated plus maze and the light-dark box tests. In addition, probiotic treatment reduced MS-induced increases in neuronal activation and brain-derived neurotrophic factor protein levels in the basolateral nucleus of amygdala (BLA) after auditory fear conditioning. Furthermore, we found that probiotic treatment significantly rescued the heightened hypothalamic-pituitary-adrenal (HPA) axis response to restraint stress in MS infant rats. Taken together, these findings suggest that probiotics can restore normal developmental trajectories of fear memory retention in MS infant rats, at least in part by normalizing HPA axis abnormalities, and that the BLA serves as a critical node to mediate these interventions. Thus, we offer a potential therapeutic intervention to protect children against the harmful effects of ELS.
UR - http://www.scopus.com/inward/record.url?scp=85065091239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065091239&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2019.04.026
DO - 10.1016/j.neuropharm.2019.04.026
M3 - Article
C2 - 31034844
AN - SCOPUS:85065091239
SN - 0028-3908
VL - 153
SP - 53
EP - 62
JO - Neuropharmacology
JF - Neuropharmacology
ER -